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Abstract
Background Achieving a normal final adult height (FH)
remains a challenge in the field of pediatric kidney trans-
plantation (KTx). To examine the optimal approach to
assuring normal FH following KTx, we retrospectively
examined the post-transplant growth and FH of pediatric
KTx recipients.
Methods Since the relevant factors affecting the FH of
children following KTx are multifactorial and notably
complex, KTx recipients with persistent good graft func-
tion and successful steroid minimization until FH attain-
ment were selected for this study.
Results Thirteen patients were enrolled in this study. The
mean estimated glomerular filtration rate was
72.1 ± 15.3 ml/min/1.73 m2, and the mean corticosteroid
dose was 0.05 ± 0.05 mg/kg on alternate days at the time
of FH attainment. Despite highly successful KTx, four
(30.8 %) patients (one who underwent KTx before puberty
and three during puberty) showed a decrease in the height
standard deviation score (hSDS) from the time of KTx until
FH attainment. Moreover, of these, two male patients had
an FH with an SD \-2.
Conclusion FH remained suboptimal despite highly suc-
cessful KTx. Not only highly successful KTx but also
further treatment such as steroid avoidance, early steroid
withdrawal or using rhGH might be necessary to assure a
normal FH in some pubertal patients.
Keywords Kidney transplantation  Children  Final adult
height
Introduction
Growth retardation is a major clinical problem in children
with chronic kidney disease [1]. An inadequate final adult
height (FH) has been associated with an unmarried status,
lower level of education and lower level of employment in
adults who underwent transplantation during childhood [2].
Since growth retardation persists in magnitude despite
kidney transplantation (KTx) [3], achieving a normal FH
remains a challenge in the field of pediatric KTx [4].
Suboptimal growth following KTx is caused by multiple
factors, the main ones being reduced graft function, corti-
costeroid treatment and age at KTx [3]. A reduced glo-
merular filtration rate (GFR) (\50 ml/min/1.73 m2) for an
extended period of time has been shown to have a signif-
icantly negative effect on FH [5], while corticosteroid
treatment on alternate days (0.5 mg/kg per alternate day)
reportedly has a salutary effect on growth [6]. The North
American Pediatric Renal Transplant Cooperative Study
(NAPRTCS) data indicated no significant change in the
height standard deviation score for chronological
age (hSDS) following KTx in the age groups 6–12 and
[13 years [7]. In addition, a preexisting height deficit at
the time of KTx [5] and reduced pubertal height gain [8]
have been shown to be associated with an inadequate FH.
Since the relevant factors affecting the FH of children
following KTx are multifactorial [1, 3], here we retro-
spectively examined the FH in KTx recipients who showed
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persistent good graft function and successful steroid min-
imization prior to achieving FH in order to examine the
optimal approach to assuring a normal FH in pediatric KTx
recipients.
Patients and methods
Patients
Between January 1996 and December 2005, 94 patients
under the age of 15 years received a renal allograft for the
first time at the Department of Pediatric Nephrology,
Tokyo Women’s Medical University. Of these, 42 patients
reached their FH by January 2010. In order to examine the
sole effects of KTx on growth, patients (n = 15) with
co-morbidities such as syndromal disorders that would
impair growth were excluded from the present study.
Patients (n = 10) with reduced graft function and/or failed
steroid minimization were also excluded. Additionally,
growth data could not be fully collected for four patients.
As a result, a total of 13 patients were enrolled in this
study. All 13 had persistent good graft function with suc-
cessful steroid minimization until attaining their FH. Good
graft function was defined as GFR [50 ml/min/ 1.73 m2
based on a previous report [5]. All 13 patients enrolled in
this study received minimal-dose corticosteroid therapy on
alternate days (\0.5 mg/kg on alternate days) [6] from 10
to 12 weeks after KTx. The present study was approved by
the local institutional review board (approval no.: 1003),
and written informed consent was obtained from all
patients.
Immunosuppression regimens
Nine patients who underwent transplantation before May
2002 received a triple immunosuppression regimen con-
sisting of cyclosporine A (CSA) or tacrolimus (FK), miz-
oribine (MZ) or mycophenolate mofetil (MMF), and
corticosteroid. Subsequently, four patients received induc-
tion therapy with basiliximab combined with the above
triple regimen. CSA/FK and MZ/MMF were started 2 days
before transplantation, and dosage adjustments of CSA and
FK were based on trough whole blood levels as previously
reported [9].
Corticosteroid was tapered to a dose of 0.5 mg/kg/day
by 4 weeks post-transplantation. Over the next 4 weeks,
the dose was further reduced by 0.25 mg/kg/day and then
converted to a dose of 0.5 mg/kg on alternate days by 10 to
12 weeks post-transplantation. Following this, the dose
was gradually reduced on alternate days, with some
patients being completely weaned during the follow-up
period at the judgment of the attending doctor.
Methods
Height values are expressed as hSDS compared with
Japanese reference data [10]. FH was defined as a height
velocity \1 cm/year for at least 1 year and radiographic
epiphyseal closure. Genetic target height was calculated as
mid-parental height ?6.5 cm for males and -6.5 cm for
females [10]. Onset of puberty was defined as achievement of
Tanner stage 2. Bone age was evaluated using the Japanese
version of the Tanner-Whitehouse 2 method [11]. Estimated
GFR was determined using the Schwartz formula [12].
Statistical analysis
Data are presented as the mean ± SD and range, unless
otherwise indicated. Bivariate associations were assessed
with the use of Fisher’s exact test or Student’s t test; only
two-tailed P values are reported. Simple linear regression
analysis was also performed. P \ 0.05 was considered
statistically significant. Excel 2010 (Microsoft, Tokyo,
Japan) was used for data analysis.
Results
Clinical data
Clinical data of the 13 study patients (6 males, 7 females) are
summarized in Table 1. Primary kidney disease was congen-
ital disorder in 9 children (hypoplastic kidney, n = 5; juvenile
nephronophthisis, n = 2; reflux nephropathy, n = 1; and
Alport’s syndrome, n = 1) and acquired disease in 4 children
(focal segmental glomerulosclerosis, n = 1; ANCA-associ-
ated nephritis, n = 1; membranous nephropathy, n = 1;
unknown, n = 1). Mean age at the start of renal replacement
therapy was 9.1 ± 3.6 years. Ten patients received peritoneal
dialysis (PD) and 3 underwent pre-emptive KTx (PKTx).
Mean duration of dialysis therapy was 2.8 ± 3.0 years, and
mean age at KTx including PKTx was 12.0 ± 2.4 years. The
deceased/living-related donor ratio was 2/11. Six patients
received recombinant human growth hormone (rhGH) therapy
before KTx, but none did so after KTx.
Mean eGFR was 86.8 ± 12.3 ml/min/1.73 m2 at 1 year
after KTx and 72.1 ± 15.3 ml/min/1.73 m2 at the time of
FH attainment. Mean dose of corticosteroid was 0.10 ±
0.06 mg/kg on alternate days at 1 year after KTx and
0.05 ± 0.05 mg/kg on alternate days at the time of FH
attainment. Additionally, 5 of the 13 patients were weaned off
corticosteroid after a mean period of 1.8 ± 0.5 years (range:
1.0–3.0 years) after KTx. By chance, all these 5 patients had
undergone transplantation before puberty. Mean hSDS at the
start of PD and at the time of KTx including PKTx were
-1.6 ± 0.8 SDS and -1.4 ± 0.7 SDS, respectively.
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FH
FH was reached at 17.2 ± 1.2 (15.9–19.0) years in males
and 16.5 ± 0.7 (15.1–17.2) years in females. FH data of the
13 study patients are shown in Table 2. Mean hSDS of the
13 patients on reaching their FH was -0.9 ± 1.0 SDS.
Mean FH (cm) and mean hSDS at FH were 163.6 ± 6.8 cm
and -1.2 ± 1.2 SDS in males and 154.5 ± 4.2 cm and
-0.7 ± 0.8 SDS in females, respectively. The FH was
6.1 ± 2.3 cm below the target height in males and
2.4 ± 2.3 cm below the target height in females. Two
males out of the total 13 patients (15.4 %) showed an FH
with an SD\-2, whereas there were no differences in their
parents’ heights between the 2 males and the remaining 11
patients.
Although there was no statistical significance (r = 0.38,
P = 0.20), a correlation was observed between hSDS at
KTx and hSDS at FH (data not shown).
Growth data of patients who underwent transplantation
before or during puberty
Seven patients (3 males, 4 females) underwent transplan-
tation before puberty and 6 (3 males, 3 females) underwent
transplantation during puberty. Figure 1 shows individual
hSDS values at the time of KTx and at the time of FH
attainment in patients following transplantation before
(n = 7) and during puberty (n = 6). Improved hSDS was
seen in 6 of 7 patients who underwent KTx before puberty
and catch-up growth, defined by hSDS [?1 [5], was seen
in 3 patients (one male, 2 females). On the other hand, no
catch-up growth was seen in the 6 patients who underwent
transplantation during puberty.
Four (30.8 %) patients (one who underwent transplan-
tation before puberty and three during puberty) showed a
decrease in hSDS from the time of KTx until FH attain-
ment, as indicated by the dashed line in Fig. 1. All four
patients had persistent good graft function (mean eGFR at
the time of FH attainment: 75.8 ± 10.1 ml/min/1.73 m2)
and received a minimum corticosteroid dose (mean corti-
costeroid dose at the time of FH attainment:
0.04 ± 0.04 mg/kg on alternate days); of these, one patient
(indicated by an arrow) discontinued steroid therapy 1 year
after KTx.
Despite optimum graft function (eGFR at the time of FH
attainment: 80.0 ml/min/1.73 m2), successful steroid
withdrawal 1 year after KTx and normal pubertal devel-
opment, the growth curve of one male patient showed
insufficient pubertal growth and subsequently an inade-
quate FH, 16.6 cm below his target height (Fig. 1 arrow,
Fig. 2).
Discussion
To examine the optimal approach to assuring a normal FH
following KTx, we retrospectively examined post-trans-
plant growth and FH of KTx recipients within our
Table 1 Clinical data of the 13 study patients
Sex (n) (%)
Male 6 (46)
Primary kidney disease (n) (%)
Congenital 9 (69)
Age at the start of RRT (years) 9.1 ± 3.6 (4.1–14.9)
PKTx (n) (%) 3 (23)
Duration of dialysis therapy (years) 2.8 ± 3.0 (0.5–10.5)
Age at KTx (years) 12.0 ± 2.4 (8.8–14.9)
Type of donor (n) (%)
Living-related 11 (85)
Growth hormone before KTx (n) (%) 6 (46)
eGFR (ml/min/1.73 m2)
1 year after KTx 86.8 ± 12.3 (67.8–112.9)
At FH attainment 72.1 ± 15.3 (51.0–104.1)
Dose of corticosteroid (mg/kg on alternate days)
1 year after KTx 0.10 ± 0.06
At FH attainment 0.05 ± 0.05
Steroid withdrawal (n) (%) 5 (38)
hSDS at start of PD -1.6 ± 0.8 (-2.6–-0.5)
hSDS at KTx -1.4 ± 0.7 (-2.5–-0.2)
Values are expressed as the number of patients (percentage) or
mean ± SD (range) unless otherwise noted
RRT renal replacement therapy, PKTx pre-emptive kidney trans-
plantation, KTx kidney transplantation, eGFR estimated glomerular
filtration rate, FH final adult height, hSDS height standard deviation
score, PD peritoneal dialysis
Table 2 Final adult height of the 13 study patients
Total (n = 13) Males (n = 6) Females (n = 7)
FH (cm) 158.7 ± 7.1 (148.7–170.0) 163.6 ± 6.8 (152.7–170.0) 154.5 ± 4.2 (148.7–161.4)
hSDS at FH -0.9 ± 1.0 (-3.1–0.6) -1.2 ± 1.2 (-3.1–-0.1) -0.7 ± 0.8 (-1.8–0.6)
Target height (cm) 164.0 ± 7.7 (154.0–176.0) 169.6 ± 5.0 (161.9–176.0) 156.9 ± 2.1 (154.0–158.5)
Values are expressed as the mean ± SD (range) unless otherwise noted
FH final adult height, hSDS height standard deviation score
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department. Since the relevant factors affecting the FH of
children following KTx are multifactorial [1, 3], 13
patients who showed persistent good graft function and
successful steroid minimization prior to achieving FH were
selected for this study. The NAPRTCS reported that GFR
[60 ml/min/ 1.73 m2 is required to maintain normal
growth [7]. Among our patients, the mean eGFR was
72.1 ± 15.3 ml/min/1.73 m2 at the time of FH attainment.
Although the precise growth-suppressing dose of
corticosteroid has not been definitively delineated [13], a
maintenance dose of 0.1 mg/kg on alternate days has been
shown to result in good post-transplant growth and FH
[14]. In our patients, the mean dose of corticosteroid was
0.05 ± 0.05 mg/kg on alternate days at the time of FH
attainment. Thus, all patients enrolled in this study under-
went highly successful KTx and reached their FH. On the
other hand, the number of enrolled patients resulted in a
small sample size because of the above-mentioned entry
criteria in this study.
Despite highly successful KTx, 4 (30.8 %) patients
showed a decrease in hSDS from the time of KTx until FH
attainment. Moreover, of these, 2 male patients had an FH
with an SD \-2.
Several factors influence pubertal growth after KTx [8],
in which a significant negative correlation has been shown
between peak height velocity during puberty and prednis-
olone dosage after KTx [15]. Maxwell et al. [16] reported
that significant catch-up growth can occur after KTx even
in children of pubertal age; the authors speculated that this
significant pubertal growth may be related to early intro-
duction of a low-dose, alternate-day steroid regimen. In
contrast, Klare et al. [17] reported that steroid withdrawal
in pubertal patients during the 4–6 months after KTx
resulted in incomplete pubertal growth despite excellent
graft function and suggested that even short-term steroid
exposure might result in a permanent growth deficit.
The steroid-tapering regimen employed in our depart-
ment is similar to that reported by Maxwell et al. [16].
Moreover, compared to Maxwell et al. [16], the mainte-
nance dose of steroid was smaller among our patients
(0.05 ± 0.05 mg/kg on alternate days in this study vs.
0.21 mg/kg on alternate days in the Maxwell et al. study).
However, in the present study, no catch-up growth was
seen among the 6 patients who underwent transplantation
during puberty; moreover, 3 patients showed a decrease in
hSDS from the time of KTx until FH attainment. Given this
Height at KTx Final adult height (SDS) 
During puberty  (n=6) Before puberty (n=7) 
Height at KTx Final adult height (SDS) 
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Fig. 1 Changes in height
standard deviation score (hSDS)
from the time of kidney
transplantation (KTx) until
attainment of FH. Changes in
the individual hSDS of patients
who underwent transplantation
before puberty (left panels) and
during puberty (right panels)
are shown. Males and females
are indicated by solid circles
and open triangles, respectively.
Patients showing a decrease of
hSDS are shown as a dashed
line
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Fig. 2 Growth curve of a male patient before and after kidney
transplantation (KTx). The patient received a kidney allograft at age
11 years. Following KTx he showed accelerated growth for 2 years.
However, despite optimum graft function (eGFR: 80.0 ml/min/1.73 m2),
successful steroid withdrawal 1 year after KTx and normal pubertal
development, the patient’s growth velocity was insufficient to provide an
adequate growth spurt during puberty. As a result, his FH was 16.6 cm
below target height. PD peritoneal dialysis, rhGH recombinant human
growth hormone
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result and considering recent reports [18–20], attainment of
a normal FH might require early steroid withdrawal
(B7 days) or complete steroid avoidance in children who
undergo transplantation during puberty.
On the other hand, an alternative approach to treating
suboptimal pubertal growth in patients who undergo
transplantation during puberty might be the use of rhGH. It
has been suggested that rhGH can be considered in pubertal
recipients in order to maximize the pubertal growth spurt
[13]. Although no patients were treated with rhGH after
KTx in this study, rhGH therapy might be an effective
option in pubertal patients not qualifying for steroid
avoidance or early steroid withdrawal [21].
In the present study, an increase in hSDS was observed
in 6 of the 7 patients who underwent transplantation before
puberty. Additionally, catch-up growth was seen in 3
patients who underwent late steroid withdrawal (1 year
after KTx). These results are in line with those of previous
reports [22, 23].
However, one male patient who underwent transplan-
tation before puberty showed a highly inadequate FH,
despite persistent good graft function and successful late
steroid withdrawal. Although delayed onset of puberty in
KTx patients reportedly results in an eventual loss of height
potential [8], no delay in pubertal onset was observed in
this patient, as shown previously [24]. In addition, no
acceleration in bone maturation was noted in this patient.
Hokken-Koelega et al. [25] and Fine used rhGH therapy in
KTx recipients during puberty and found that rhGH
increased the increment in height [3]. Therefore, appro-
priate use of rhGH is an additional key point in attaining a
normal FH in pubertal children following KTx [13].
Finally, a preexisting height deficit at the time of KTx is
reportedly associated with an inadequate FH [5]. In the
present study, 4 patients (30.8 %) did not attain FH within
the predicted target height interval; one of these was due to
a preexisting height deficit at the time of KTx. Therefore,
efforts to avoid a height deficit before KTx are also
essential in attaining a normal FH in children following
KTx [4, 13].
In conclusion, the FH observed here remained subopti-
mal despite highly successful KTx. Not only highly suc-
cessful KTx, but also further treatment such as steroid
avoidance, early steroid withdrawal or using rhGH might
be necessary to assure a normal FH in some pubertal
patients. Further studies are required to verify these
approaches to treating suboptimal pubertal growth.
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